Evidence map›Paper›PMID 23097297›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2013

Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease.

Lap Ho, Mario G Ferruzzi, Elsa M Janle, Jun Wang, Bing Gong, Tzu-Ying Chen, Jessica Lobo, Bruce Cooper, Qing Li Wu, Stephen T Talcott and 3 more

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 202 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. TargetingJournal of pharmaceutical analysis · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. A Mixture ofPlants (Basel, Switzerland) · 2023
    Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Lap HoDepartment of Neurology, Mt. Sinai School of Medicine, New York, NY 10029, USA.
Mario G Ferruzzi
Elsa M Janle
Jun Wang
Bing Gong
Tzu-Ying Chen
Jessica Lobo
Bruce Cooper
Qing Li Wu
Stephen T Talcott
Susan S Percival
James E Simon
Giulio Maria Pasinetti
Purdue University West Lafayette · USIcahn School of Medicine at Mount Sinai · USDepartment of Plant Biology · USRutgers, The State University of New Jersey · USTexas A&M University · USUniversity of Florida · US

Funding

Resveratrol & Natur Polyphenols: Mech of Proteolitic Clear of AB/Marambaud, PhilP01AT004511 · NCCIH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PASINETTI, GIULIO MARIA · 2007 to 2012
$8.0M
NCCIH NIH HHS P01 AT004511
6 · The paper itself

Abstract

Epidemiological and preclinical studies indicate that polyphenol intake from moderate consumption of red wines may lower the relative risk for developing Alzheimer's disease (AD) dementia. There is limited information regarding the specific biological activities and cellular and molecular mechanisms by which wine polyphenolic components might modulate AD. We assessed accumulations of polyphenols in the rat brain following oral dosage with a Cabernet Sauvignon red wine and tested brain-targeted polyphenols for potential beneficial AD disease-modifying activities. We identified accumulations of select polyphenolic metabolites in the brain. We demonstrated that, in comparison to vehicle-control treatment, one of the brain-targeted polyphenol metabolites, quercetin-3-O-glucuronide, significantly reduced the generation of β-amyloid (Aβ) peptides by primary neuron cultures generated from the Tg2576 AD mouse model. Another brain-targeted metabolite, malvidin-3-O-glucoside, had no detectable effect on Aβ generation. Moreover, in an in vitro analysis using the photo-induced cross-linking of unmodified proteins (PICUP) technique, we found that quercetin-3-O-glucuronide is also capable of interfering with the initial protein-protein interaction of Aβ(1-40) and Aβ(1-42) that is necessary for the formation of neurotoxic oligomeric Aβ species. Lastly, we found that quercetin-3-O-glucuronide treatment, compared to vehicle-control treatment, significantly improved AD-type deficits in hippocampal formation basal synaptic transmission and long-term potentiation, possibly through mechanisms involving the activation of the c-Jun N-terminal kinases and the mitogen-activated protein kinase signaling pathways. Brain-targeted quercetin-3-O-glucuronide may simultaneously modulate multiple independent AD disease-modifying mechanisms and, as such, may contribute to the benefits of dietary supplementation with red wines as an effective intervention for AD.

Indexed as

Administration, OralAlzheimer DiseaseAmyloid beta-PeptidesAnimalsAnthocyaninsBiological AvailabilityBrainCells, CulturedDietary SupplementsDisease Models, AnimalGlucosidesHumansMaleMiceMice, TransgenicNeuronal PlasticityAmyloid beta-PeptidesAnthocyaninsGlucosidesmalvidin-3-glucosideNeuroprotective AgentsPolyphenolsQuercetinquercetin 3-O-glucuronide

Identifiers

PMID23097297
PMCPMC3545533
OpenAlexW2117720005

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.